An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer.
In just a few years’ time, Ipilumumab could be approved as a treatment for the world’s third-most common type of cancer.
The immunotherapeutic agent Ipilumumab has been shown to have a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy. These are the words of a core statement from a study, recently published in the highly respected journal “The Lancet Oncology”, which was set up based on collaboration between the world’s leading centres for the research and treatment of prostate cancer.
The scientists investigated the extent to which immunotherapy with this agent is also suitable for the more common type of advanced prostate cancer. The medication is already being successfully used as immunotherapy for advanced melanoma – a comparatively rare type of cancer.
Read more . . .
The Latest on: Immunotherapy
[google_news title=”” keyword=”Immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunotherapy
- Immunotherapy and hay feveron April 26, 2024 at 2:09 am
This can mean taking a regular dose of antihistamines, nasal sprays and eye drops to try to relieve the irritating symptoms like a runny nose, itchy eyes and persistent sneezing. But for others, the ...
- FDA Approves New Type of Immunotherapy for Early Bladder Canceron April 25, 2024 at 1:19 pm
Anktiva, an IL-15 agonist, also shows promise for other malignancies, including non-small-cell lung cancer, and even for HIV.
- Vitamin D may balance gut microbiome to give cancer immunotherapy a booston April 25, 2024 at 12:30 pm
A new study in mice found that dietary vitamin D plays a role in balancing the gut microbiome and improving the way cancer immunotherapy works to fight tumors.
- Immunotherapy Combination Approved for Non-Muscle Invasive Bladder Canceron April 24, 2024 at 2:43 am
FDA approves immunotherapy drug combo for non-muscle invasive bladder cancer after UCLA-led research shows improved outcomes for patients.
- Page settingson April 23, 2024 at 10:44 am
The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy ...
- Scientists making progress in less toxic cancer treatment called immunotherapyon April 22, 2024 at 3:04 pm
Scientists are making progress in using less toxic immunotherapy instead of traditional chemotherapy to fight cancer.
- Improving cancer immunotherapy by prolonging T-cell survivalon April 22, 2024 at 1:20 pm
In the past decade, immunotherapy has emerged as the fourth pillar of cancer treatment, joining surgery, radiotherapy and chemotherapy. It is an approved treatment for 15 cancers, including melanoma ...
- Has Immunotherapy Found Its Place in Pancreatic Cancer?on April 22, 2024 at 4:09 am
A new study suggested that adding nivolumab to neoadjuvant treatment improves outcomes in patients with borderline resectable pancreatic cancer.
- Immunotherapy Developed To Localize Cancer-Killing Moleculeson April 22, 2024 at 2:12 am
A new immunotherapy has been developed that localizes cytokines to tumors for weeks while preserving their activity.
- New Cancer Immunotherapy Balances Efficacy and Safetyon April 20, 2024 at 5:00 am
The new immunotherapy employing cytokine proteins offers a promising treatment avenue, targeting tumors while preserving healthy cells from damage.
via Bing News